GlassScriptPhysician profile
Laura Hobson
NPI 1568988574
$7,332.97
in general payments reported to CMS, 2019-2025
26 companies · $896 in 2025
The $896 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $985 · 2022: $1,244 · 2023: $2,084 · 2024: $2,125 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,092 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,092.48 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,105.22 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $977.59 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $885.53 | 2021-2025 | Caplyta |
| Lundbeck LLC | $591.17 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $546.73 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $376.05 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $345.17 | 2021-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $200.63 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $186.20 | 2022-2024 | Gralise, Loreev Xr, Teriparatide |
| Sunovion Pharmaceuticals INC. | $179.37 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $143.32 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $142.44 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $134.73 | 2023 | Quviviq |
| Alkermes, INC. | $116.62 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $106.75 | 2022-2024 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $56.60 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $46.71 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $44.53 | 2021-2023 | Xelstrym |
| Tris Pharma INC | $38.31 | 2022-2023 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $21.94 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.13 | 2021 | |
| Corium, LLC | $15.83 | 2021 | |
| Bioxcel Therapeutics, INC. | $14.93 | 2023 | Igalmi |
| Supernus Pharmaceuticals, INC. | $14.44 | 2025 | Qelbree |
| Acadia Pharmaceuticals INC | $14.31 | 2021 | |
| Bausch Health US, LLC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.